Person: DURDU, BÜLENT
5 results
Search Results
Now showing 1 - 5 of 5
Publication Open Access Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19(2020-09-25T00:00:00Z) Koç, Mm; Kalkan, Yazıcı; Çetin, Nesibe Selma; Doymaz, Mz; Sümbül, B; Durdu, B; YAZICI, MERVE; MERİÇ KOÇ, MELİHA; ÇETİN, NESİBE SELMA; KARAASLAN, ELİF; OKAY, GÜLAY; DURDU, BÜLENT; SÜMBÜL, BİLGE; DOYMAZ, MEHMET ZIYAThe recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.Publication Open Access COVİD-19 infection in a membranous nephropathy patient treated with rituximab.(2020-09-04T00:00:00Z) Elcioglu, Omer Celal; Artan, Ayse Serra; Mirioglu, Safak; Gursu, Meltem; Durdu, Bulent; Koc, Meliha Meric; Okyaltirik, Fatmanur; Gultekin, Mehmet Ali; Kazancioglu, Rümeyza; ELÇİOĞLU, ÖMER CELAL; MİRİOĞLU, ŞAFAK; GÜRSU, MELTEM; DURDU, BÜLENT; MERİÇ KOÇ, MELİHA; OKYALTIRIK, FATMANUR; GÜLTEKİN, MEHMET ALİ; KAZANCIOĞLU, RÜMEYZAWhile COVID-19 pandemic continues to afect our country and most countries in the world, we have to make some changes both in our social life and our approach to healthcare. We have to struggle with the pandemic on one hand and also try to follow up and treat our patients with chronic diseases in the most appropriate way. In this period, one of our group of patients who are challenging us for follow-up and treatment are those who should start or continue to use immunosuppressive therapy. In order to contribute to the accumulation of knowledge in this area, we wanted to report a patient who was followed up with the diagnosis of COVID-19 and had been administered rituximab very recently due to a nephrotic syndrome caused by membranous nephropathy.Publication Open Access Investigation the Relationship Between Body Mass Index and Mortality in COVID-19 Patients(2021-02-01T00:00:00Z) BOLUKÇU, SİBEL; ÖZMEN, MEHMET EMİN; EKŞİ, ÇAĞLA; OKAY, GÜLAY; SÜMBÜL, BİLGE; KAÇMAZ, ASİYE BAHAR; DURDU, BÜLENT; AKKOYUNLU, YASEMİN; MERİÇ KOÇ, MELİHA; BOLUKÇU, SİBEL; ÖZMEN, MEHMET EMİN; EKŞİ, ÇAĞLA; OKAY, GÜLAY; SÜMBÜL, BİLGE; KAÇMAZ, ASİYE BAHAR; DURDU, BÜLENT; AKKOYUNLU, YASEMİN; MERİÇ KOÇ, MELİHAObjective: Obesity might be a risk factor for patients with Coronavirus disease-19 (COVID-19). We aimed to investigate the association of the obesity with intensive care need and mortality caused by severe acute respiratory syndrome-CoV-2 (SARS-CoV-2) infection in this retrospective cohort. Methods: Between March 11th and May 1st, 135 patients, who were treated in our clinic, were enrolled in the study. Body mass index (BMIs) of the patients were grouped according as WHO criteria (<25 kg/m(2): normal, 25 30 kg/m(2): overweight, >30 kg/m(2): obese). Results: Of our patients, 34.1% (n=46) were obese. Mean BM! of the mortality group was 31.2 kg/m(2) and was not different from that of the survivors (p=0.09), However, mean BMI of the patients, in whom intensive care was needed, teas 31.2 kg/m(2) and higher than that of those intensive care was nut needed (p=0.04). In subgroup analyses, obesity (BMI >31) kg/m(2)) was more common among mortality group versus survivors in males older than 60 years old (p=0.03). Conclusion: Obesity with associated disorders are negative prognostic factors for COVID-19 and should be tackled as the end of the pandemic is obscure.Publication Open Access COVID-19 and Influenza Coexistence(2021-02-01T00:00:00Z) Uslu Ersoz, Ayse Betul; BOLUKÇU, SİBEL; Andic, Nurgul; Karakus, Dilara; OKAY, GÜLAY; SÜMBÜL, BİLGE; KAÇMAZ, ASİYE BAHAR; DURDU, BÜLENT; AKKOYUNLU, YASEMİN; MERİÇ KOÇ, MELİHA; USLU, AYŞE BETÜL; BOLUKÇU, SİBEL; ANDIÇ, NURGÜL; OKAY, GÜLAY; SÜMBÜL, BİLGE; KAÇMAZ, ASİYE BAHAR; DURDU, BÜLENT; AKKOYUNLU, YASEMİN; MERİÇ KOÇ, MELİHAObjective: Viral pneumonia cases occur quite frequently in the community. The rate of viral infections in community-acquired pneumonia is about 25%. severe acute respiratory syndrome coronas i rus-2 (SARS-CoV-2) and influenza are also viruses that can cause pneumonia. In this study. we aimed to determine the rate of influenza co-infection in Coronavirus disease-19 (COVID-19) Cases. Methods: The data of adult patients who applied to Bezmialem Vakif University Hospital between March 6, 2020, and May 21, 2020, which were positive with the SARS-CoV-2 polymerase chain reaction (PCR) test and influenza antigen test were retrospectively scanned from the hospital automation system. Results: SARS-CoV-2 PCR test was found positive in 498 adult patients who applied to our hospital. Two hundrend-sixty of these patients were hospitalized and 238 were followed up on an outpatient basis. In 88 patients SARS-CoV-2 PCR and influenza antigen were studied, and 6 of them had positive influenza antigen. COVID-19 and influenza co- i n feet ion was not detected. Conclusion: In order to determine the exact rate of influenza and COVID-19 co-infection, it is necessary to evaluate the patients who applied with the appropriate clinical picture from the beginning of the seasonal influenza period by using reverse transcription-PCR fur these two viral infections, if possible. Further research is needed in this area.Publication Open Access Identification of Drug-Related Problems and Investigation of Related Factors in Patients with COVID-19: An Observational Study(2022-12-01) Bektay M. Y.; Sancar M.; Okyaltırık F.; Durdu B.; İzzettin F. V.; BEKTAY, MUHAMMED YUNUS; OKYALTIRIK, FATMANUR; DURDU, BÜLENT; İZZETTİN, FIKRET VEHBIObjective: Clinical prognosis of coronavirus disease-19 (COVID-19) may be severe and unexpected. Patients may quickly progress to respiratory failure, infections, multiple organ dysfunction, and sepsis. The main objective of this study is to investigate the drug-related problems of patients with COVID-19 and related factors. Method: A prospective observational study was conducted on patients with COVID-19 between September 2020 and May 2021. Patients’ demographics, comorbid diseases, prescribed medicines and laboratory findings were recorded. Drug-related problems (DRPs) were identified by a clinical pharmacist according to recent guidelines, UpToDate® clinical decision support system and evidence-based medicine. Results: The median age of 107 patients was 64 and 50.46% of them were male. The median number of comorbidities was 3 (2-4) per patient. The majority of the patients had at least one comorbidity (88.79%) other than COVID-19 and the most frequent comorbidities were hypertension, diabetes mellitus and coronary artery disease. The total number of DRPs was recorded as 201 and at least one DRP was seen in 75 out of 107 patients. The median number of DRPs was 2 (0-8). In multivariate model, number of comorbidities (odss ratio (OR)=1.952; 95% confidence interval (CI)=1.07-3.54, p<0.05, number of medications (OR=1.344; 95% CI=1.12-1.61, p<0.001), and serum potassium levels (OR=5.252; 95% CI=1.57-17.56, p<0.001) were the factors related with DRP. Conclusion: This study highlights the DRPs and related factors in patients with COVID 19 in hospital settings. Considering unknown features of the infection and multiple medication use, DRPs are likely to occur. It would be beneficial to consider the related factors in order to reduce the number of the DRPs.